2-Isopropyl-4H-oxazol-5-one

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Isopropyl-4H-oxazol-5-one
• 英文别名: 2-propan-2-yl-4H-1,3-oxazol-5-one
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: ODBMUGHHORVMPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  triphenylphosphine dibromide 1:1 addition complex 、 2-Isopropyl-4H-oxazol-5-one 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 2-Propan-2-yl-4-(triphenyl-lambda5-phosphanylidene)-1,3-oxazol-5-one
  参考文献：
  名称：

  4-Phosphoranylidene-5(4H)-oxazolones ? A novel synthesis and properties

  摘要：

  4-Phosphoranylidene-5(4H)-oxazolones (2), a hardly known class of phosphorus ylides, were readily prepared from 4-unsubstituted-5-(4H)-oxazolones (1) by treatment with Ph(3)P-Br-2, Bu(3)P-Br-2, Ph(3)P-CCl4, or Ph(3)P-CB4 adducts in the presence of triethylamine in CH2Cl2 at room temperature in a novel, efficient one-pot procedure. The spectroscopic properties of the ylides are reported and discussed.

  DOI：

  10.1007/bf00807402
• 作为产物：
  描述：

  2-(异丁基氨基)乙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-Isopropyl-4H-oxazol-5-one
  参考文献：
  名称：

  4-Phosphoranylidene-5(4H)-oxazolones ? A novel synthesis and properties

  摘要：

  4-Phosphoranylidene-5(4H)-oxazolones (2), a hardly known class of phosphorus ylides, were readily prepared from 4-unsubstituted-5-(4H)-oxazolones (1) by treatment with Ph(3)P-Br-2, Bu(3)P-Br-2, Ph(3)P-CCl4, or Ph(3)P-CB4 adducts in the presence of triethylamine in CH2Cl2 at room temperature in a novel, efficient one-pot procedure. The spectroscopic properties of the ylides are reported and discussed.

  DOI：

  10.1007/bf00807402

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180086747A1

  公开（公告）日：2018-03-29

  The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein.

  本申请提供了化合物I或IA的化学式，或其药用可接受盐、异构体、互变异构体或其混合物，其中s、t、m、n、R1、R2、R3、R4、R5、R6和R7如本文所述。
• 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists
  申请人：Hale Jeffrey John

  公开号：US20090042954A1

  公开（公告）日：2009-02-12

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P 1 /Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖I式化合物，以及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞移行，将淋巴细胞隔离在二次淋巴组织中，并增强血管完整性，具有免疫抑制，抗炎和止血活性。本发明还涉及含有这些化合物的制药组合物和治疗或预防的方法。
• (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists
  申请人：Colandrea Vincent J.

  公开号：US20080249093A1

  公开（公告）日：2008-10-09

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P 1 /Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖以下I式化合物及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞的转移，将淋巴细胞隔离在二级淋巴组织中，并增强血管完整性，具有免疫抑制，抗炎和止血活性。本发明还涉及含有这些化合物的制药组合物和治疗或预防的方法。
• Heterocyclic Inhibitors of MEK and Methods of Use Thereof
  申请人：Marlow Allison L.

  公开号：US20110288092A1

  公开（公告）日：2011-11-24

  Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 , R 8 , R 9 and W are as defined in the specification.

  本发明涉及治疗增殖过度性疾病的方法、治疗炎症性疾病的方法以及抑制哺乳动物中MEK活性的方法，其中包括向哺乳动物中给予一种或多种Formula Vor化合物或其药学上可接受的盐的有效量，其中R1、R2、R7、R8、R9和W如规范中所定义。
• HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
  申请人：Marlow Allison L.

  公开号：US20110183981A1

  公开（公告）日：2011-07-28

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中R1、R2、R7、R8和R9，W、X和Y的定义如规范中所述。这些化合物是MEK抑制剂，可用于治疗哺乳动物的高增殖性疾病，如癌症和炎症以及炎症病症。本发明还涉及使用这些化合物治疗哺乳动物的高增殖性疾病的方法和包含这些化合物的制药组合物。